Immuno-Oncology

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

Thomas Powles MBBS, MRCP, MD, discusses the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer.